FDA Approves Pivotal COSIRA-II Trial for Neovasc’a Reducer System


November 6, 2017—Neovasc Inc. announced that it has received approval from the US Food and Drug Administration (FDA) to initiate the COSIRA-II pivotal trial under an investigational device exemption. The trial's purpose will be to demonstrate the safety and effectiveness of the company's Reducer system for treatment of patients with refractory angina. When the trial is completed, the data are intended to support an application to the FDA for approval to begin marketing Reducer in the United States.

According to the company, COSIRA-II will be a multicenter, randomized (1:1 ratio), double-blinded, sham-controlled clinical trial that will enroll 380 patients at up to 35 investigational centers across North America. Neovasc is currently evaluating start-up timelines and funding options for the COSIRA-II trial.

The COSIRA-II trial design is similar to the COSIRA study, which was a 104-patient study conducted in Europe and Canada. In February 2015, the positive results of that study were published by Stefan Verheye, MD, et al in The New England Journal of Medicine (2015;372:519–527).

The company advised that the Reducer has received European CE Mark approval for the treatment of refractory angina. The Reducer can provide relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.